Study | Year | Country | Cancer types | Cases/controls | Age (years) | Follow-up time | Method | Cut-off value (positive/high) | Survival outcomes | Source of data | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|
Asleh et al. [21] | 2018 | Canada | IBC | 339/2895 | NR | 12.6 years (median) | IHC | A2 > 0 | BCSS(U), BCSS(M) | Direct | 8 |
Asleh et al. [52] | 2019 | Denmark | MBC | 29/216 | NR | NR | IHC | A2 > 0 | OS(U), OS(M) PFS(U), PFS(M) | Direct | 8 |
De Lara et al. [22] | 2019 | Sweden | MBC | 25/110 | NR | 10 years | IHC | A2 > 0 | OS(U), DMFS(U) OS(M), DMFS(M) | Curve Direct | 8 |
Gao et al. [23] | 2014 | China | BC | 42/109 | 32–79 | NR | IHC | A1 > 0 | BCSS(U) | Curve | 8 |
Krüger et al. [24] | 2017 | Norway | IBC | I: 50/47 II: 35/244 III: 51/130 IV: 44/143 | I: 50–69 II: 50–69 III, IV: NR | I: 13 years (median) II, III, IV: NR | IHC | At least 3 clearly positive cells | I: BCSS(U), BCSS(M) II, III, IV: NR | Direct | 8 |
Liu et al. [26] | 2010 | China | DCIS, IDC | 24/126 | 27–80 | NR | IHC | A5 > 0 | BCSS(U) | Curve | 8 |
Liu et al. [25] | 2012 | China | DCIS, IDC | 62/241 | NR | 7.5 years | IHC | A5 > 0 | BCSS(U) | Curve | 7 |
Meisen et al. [54] | 2014 | USA | BC | 83/83 | NR | NR | qRT-PCR | Median | DMFS(U) | Curve | 7 |
Nowak et al. [50] | 2017 | Poland | IDC | 109 (total) | NR | NR | IHC | Nestin+ MVD > 75.76 (median) | OS(U), OS(M), RFS(U) | Direct curve | 7 |
Nowak et al. [51] | 2018 | Poland | IDC | 39/83 | NR | 1–80 months | IHC | A3*B1 > 0 | OS(U) | Curve | 7 |
Parry et al. [27] | 2008 | UK | IBC | 20/223 | NR | 5.2–135.3 months | IHC | A5 > 0 | BCSS(U) | Curve | 8 |
Piras et al. [28] | 2011 | Italy | BC | 28/25 | 32–67 | 82–194 months | IHC | A6 > 0 | OS(U) | Curve | 8 |
Tampaki et al. [55] | 2017 | Greece | BC | 26/115 | NR | NR | IHC | A4 > 0 | RFS(U), RFS(M) | Curve direct | 7 |
Zhao et al. [20] | 2014 | China | TNBC | 41/109 | NR | NR | IHC | A1 > 0 | OS(U) | Curve | 7 |
Zhu et al. [56] | 2009 | China | DCIS, IDC | 20/100 | NR | NR | IHC | A5 > 0 | NR | NR | – |